DOP2001000210A - USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS - Google Patents
USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSISInfo
- Publication number
- DOP2001000210A DOP2001000210A DO2001000210A DO2001000210A DOP2001000210A DO P2001000210 A DOP2001000210 A DO P2001000210A DO 2001000210 A DO2001000210 A DO 2001000210A DO 2001000210 A DO2001000210 A DO 2001000210A DO P2001000210 A DOP2001000210 A DO P2001000210A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- vapes
- organ fibrosis
- fibrosis
- parapoxvirus ovis
- against organ
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24261—Methods of inactivation or attenuation
- C12N2710/24264—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Addiction (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
PROBLEM TO BE SOLVED: To provide a medicament having a preventive or curative effect on organ fibrosis in humans.SOLUTION: The medicament shows the effect to a common final path to all diseases connected to fibrosis, using the fact that a preparation of parapoxviruses, obtained from the strains D 1701, orf-11, Greek orf strain 176, Greek orf strain 155, and the New Zealand (NZ) strains inhibit transformation of hepatic stellate cells into collagen producing-myofibroblast type.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10033581 | 2000-07-11 | ||
DE10122233A DE10122233A1 (en) | 2000-07-11 | 2001-05-08 | Use of strains of the Parapoxvirus ovis against organ fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2001000210A true DOP2001000210A (en) | 2002-12-15 |
Family
ID=7648485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2001000210A DOP2001000210A (en) | 2000-07-11 | 2001-07-11 | USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS |
Country Status (14)
Country | Link |
---|---|
JP (2) | JP5587950B2 (en) |
KR (1) | KR100845643B1 (en) |
CN (1) | CN101444539B (en) |
AT (1) | ATE445413T1 (en) |
BR (1) | BRPI0112411B8 (en) |
DE (2) | DE10122233A1 (en) |
DK (1) | DK1303302T3 (en) |
DO (1) | DOP2001000210A (en) |
EC (1) | ECSP034420A (en) |
ES (1) | ES2332355T3 (en) |
PE (1) | PE20020218A1 (en) |
PT (1) | PT1303302E (en) |
SV (1) | SV2002000527A (en) |
ZA (1) | ZA200300276B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102015111756A1 (en) * | 2015-07-20 | 2017-01-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Recombinant Orf virus vector |
JP6875745B2 (en) * | 2016-02-16 | 2021-05-26 | 国立大学法人大阪大学 | Pharmaceutical composition for treating fibrosis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4405841C1 (en) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotent non-specific immunity inducers based on combinations of poxvirus components, processes for their preparation and their use as pharmaceuticals |
BR9708679A (en) * | 1996-04-15 | 2000-01-04 | Anton Mayr | Use of pox inducers, and, process for auxiliary treatment of patients undergoing chemotherapy or radiotherapy. |
-
2001
- 2001-05-08 DE DE10122233A patent/DE10122233A1/en not_active Withdrawn
- 2001-07-10 PE PE2001000681A patent/PE20020218A1/en not_active Application Discontinuation
- 2001-07-11 DK DK01965110.8T patent/DK1303302T3/en active
- 2001-07-11 KR KR1020037000310A patent/KR100845643B1/en active IP Right Grant
- 2001-07-11 PT PT01965110T patent/PT1303302E/en unknown
- 2001-07-11 DO DO2001000210A patent/DOP2001000210A/en unknown
- 2001-07-11 CN CN200810149856.XA patent/CN101444539B/en not_active Expired - Lifetime
- 2001-07-11 BR BR0112411-0 patent/BRPI0112411B8/en not_active IP Right Cessation
- 2001-07-11 SV SV2001000527A patent/SV2002000527A/en not_active Application Discontinuation
- 2001-07-11 AT AT01965110T patent/ATE445413T1/en active
- 2001-07-11 ES ES01965110T patent/ES2332355T3/en not_active Expired - Lifetime
- 2001-07-11 DE DE50115181T patent/DE50115181D1/en not_active Expired - Lifetime
-
2003
- 2003-01-10 EC EC2003004420A patent/ECSP034420A/en unknown
- 2003-01-10 ZA ZA200300276A patent/ZA200300276B/en unknown
-
2012
- 2012-06-28 JP JP2012145847A patent/JP5587950B2/en not_active Expired - Lifetime
-
2014
- 2014-06-17 JP JP2014124405A patent/JP5950964B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE50115181D1 (en) | 2009-11-26 |
JP5950964B2 (en) | 2016-07-13 |
KR20030019562A (en) | 2003-03-06 |
BRPI0112411B1 (en) | 2018-02-27 |
SV2002000527A (en) | 2002-10-24 |
BRPI0112411B8 (en) | 2021-05-25 |
BR0112411A (en) | 2003-05-27 |
PT1303302E (en) | 2009-11-11 |
CN101444539B (en) | 2016-07-06 |
ECSP034420A (en) | 2003-03-10 |
KR100845643B1 (en) | 2008-07-10 |
JP2012214492A (en) | 2012-11-08 |
DK1303302T3 (en) | 2010-02-08 |
PE20020218A1 (en) | 2002-05-19 |
ES2332355T3 (en) | 2010-02-03 |
JP2014196329A (en) | 2014-10-16 |
ATE445413T1 (en) | 2009-10-15 |
DE10122233A1 (en) | 2002-01-24 |
CN101444539A (en) | 2009-06-03 |
JP5587950B2 (en) | 2014-09-10 |
ZA200300276B (en) | 2004-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI20011851A (en) | Fluoxetine or its acid addition salt dispersible tablet | |
MY144292A (en) | Method of reducing oral tissue inflammation using magnolia extract | |
DK1418942T3 (en) | Poxvirus-containing compositions and processes for their preparation | |
CA2281193A1 (en) | Use of at least one extract of rosaceae, genus sanguisorba officinalis, to promote pigmentation of the skin, hair and/or body hair | |
ES2127613T3 (en) | USE OF A TNF-ALPHA ANTAGONIST FOR THE TREATMENT OF CUTANEOUS REDDES OF NEUROGENOUS ORIGIN. | |
DOP2001000210A (en) | USE OF PARAPOXVIRUS OVIS VAPES AGAINST ORGAN FIBROSIS | |
AU2309102A (en) | Dermatological formulations | |
PT1091740E (en) | SEMI-SOLID AQUEOUS PREPARATIONS FOR ORAL ADMINISTRATION OF TOLTRAZURIL-SULFONE | |
AU5487101A (en) | Cosmetic or dermatological product comprising a freeze-dried hydrocolloid composition | |
MXPA05005911A (en) | Use of docosahexanoic acid as active substance for the treatment of lipodystrophy. | |
NO20013605L (en) | Preparation for warts | |
EP1038529A3 (en) | Agent for increasing chemokine production | |
WO2022169336A3 (en) | Pharmaceutical composition for prevention or treatment of fibrosis comprising leuconostoc citreum strain as active ingredient | |
Fox | Stop Trying Too Hard to Kill Bacteria | |
Vazquez | How low can you go | |
ES2130069B1 (en) | PHARMACEUTICAL PREPARATION WITH DELAYED RELEASE OF THE ACTIVE PRODUCT. | |
Matts et al. | The ‘‘dry skin cycle’’: introducing a new model for the induction and propagation of xerosis in normal skin | |
BRPI0705224A2 (en) | use of pau ferro extract (caesalpinia ferrea mart.) in cosmetic and pharmaceutical formulations as a depigmenting / skin whitening agent | |
GEP20002176B (en) | Ointment “Bentastatin” for Treatment of Fungus Diseases of Skin and Mucous Membrane and Inflammatory Processes | |
AP2001002323A0 (en) | The use of aqueous herbal preparation, pmz10, as an alternative remedy in the treatment of HIV/AIDS. | |
AR031146A1 (en) | A STABLE COMPOSITION FOR THE TOPICAL TREATMENT OF SKIN ULCERS OF THE TYPE THAT CORRESPONDS TO A GEL OR MUCILAGINOUS MASS AND PROCEDURE FOR PREPARATION | |
GEU2001773Y (en) | Medicinal Means of Antioxidant Activity | |
IT1274733B (en) | Strain of the genus Lactobacillus of human origin and its uses |